your market intelligence analyst
Search Results
64 results
Your search is now limited to «FDA Actions» expert search.
PMLiVE 10/22/2019 04:26
The FDA approval comes on the back of the DECLARE-TIMI 58 clinical trial, which showed that Farxiga (dapagliflozin) was able to reduce hospitalisations for heart failure and cardiovascular death in a broad diabetes patient population, most of whom had no cardiovascular disease at enrolment, compared with placebo ...
More from PMLiVE:
AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors ...
More from Pharmaceutical Business Review:
Healio News 10/21/2019 10:03
In DAPA-HF, dapagliflozin added to standard therapy for heart failure was associated with reduced risk for worsening heart failure and CV death for patients with heart failure with and without diabetes.
More from Healio News:
ENDPOINTS 10/21/2019 08:55
The results showed that the Farxiga treatment did trigger a lower rate of hospitalization for heart failure — but the therapy was not better or worse than placebo in its impact on the rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke.
More from ENDPOINTS:
The data has driven rapid adoption across multiple NHS trusts and international markets, as well as the expanded FDA clearance.
More from Healthcare Sales & Marketing Network: 10/01/2019 00:10
Given the significant unmet need for heart failure treatments that are proven safe and effective in pediatric patients, this approval and the availability of a new treatment option is great news for these children and their families,” said Andrea Baer, Executive Director at ...
More from
PR Newswire 09/30/2019 08:30
Specified secondary outcomes included a composite of heart attack, stroke, or CV death and a composite of CV death or hospitalization for heart failure.
More from PR Newswire:
CorMatrix Cardiovascular, a developer of regenerative cardiovascular medical devices, today announced it has completed enrollment of the adult arm of its FDA early feasibility IDE study for the Cor TRICUSPID ECM cardiac valve* for adults with endocarditis and for pediatric patients with ...
More from Medical Devices Business Review:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications